JP2007533299A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533299A5
JP2007533299A5 JP2006534807A JP2006534807A JP2007533299A5 JP 2007533299 A5 JP2007533299 A5 JP 2007533299A5 JP 2006534807 A JP2006534807 A JP 2006534807A JP 2006534807 A JP2006534807 A JP 2006534807A JP 2007533299 A5 JP2007533299 A5 JP 2007533299A5
Authority
JP
Japan
Prior art keywords
antibody
activity
cell
content
galactosyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533299A (ja
Filing date
Publication date
Priority claimed from FR0312229A external-priority patent/FR2861080B1/fr
Application filed filed Critical
Publication of JP2007533299A publication Critical patent/JP2007533299A/ja
Publication of JP2007533299A5 publication Critical patent/JP2007533299A5/ja
Pending legal-status Critical Current

Links

JP2006534807A 2003-10-20 2004-10-20 抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連 Pending JP2007533299A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312229A FR2861080B1 (fr) 2003-10-20 2003-10-20 Anticorps presentant un taux de fucose et de galactose optimise
PCT/FR2004/002686 WO2005040221A1 (fr) 2003-10-20 2004-10-20 Correlation du ratio taux de fucose / taux de galactose d’anticorps anti rhesus d et anti hla-dr avec l’activite adcc

Publications (2)

Publication Number Publication Date
JP2007533299A JP2007533299A (ja) 2007-11-22
JP2007533299A5 true JP2007533299A5 (https=) 2011-02-17

Family

ID=34385294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534807A Pending JP2007533299A (ja) 2003-10-20 2004-10-20 抗ｒｈｅｓｕｓ−ｄおよび抗ｈｌａ−ｄｒ抗体のフコース含量／ガラクトース含量の比とａｄｃｃ活性の間の関連

Country Status (9)

Country Link
US (1) US20070015239A1 (https=)
EP (1) EP1675873A1 (https=)
JP (1) JP2007533299A (https=)
AU (1) AU2004283924B2 (https=)
BR (1) BRPI0415565A (https=)
CA (1) CA2542881A1 (https=)
FR (1) FR2861080B1 (https=)
IL (1) IL174896A0 (https=)
WO (1) WO2005040221A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP3539981A1 (en) * 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
AU2013203482B2 (en) * 2006-09-10 2015-08-27 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
KR20110084196A (ko) 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
MX2011010166A (es) * 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
EP2374816B1 (en) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409989A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Method to improve glycosylation profile for antibody
WO2012105699A1 (ja) * 2011-02-03 2012-08-09 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN104168913A (zh) * 2011-08-10 2014-11-26 法国化学与生物科技实验室 高半乳糖基化抗体
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014125377A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594230A1 (en) * 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
US11780934B2 (en) 2016-02-05 2023-10-10 Institut Pasteur Use of inhibitors of ADAM12 as adjuvants in tumor therapies
EA202090020A1 (ru) 2017-07-10 2020-04-28 Интернэшнл - Драг - Дивелопмент - Байотек Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
AU2023410277A1 (en) 2022-12-23 2025-06-12 Iomx Therapeutics Ag Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
EP4491230A1 (en) 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316463A1 (en) * 1987-11-13 1989-05-24 Northwestern University Murine hybridoma lym-1 and diagnostic antibody produced thereby
SE9203479L (sv) * 1992-01-20 1993-07-21 Rso Corp Saett och anordning vid elektronisk identifiering
FR2776096B1 (fr) * 1998-03-12 2000-06-23 Commissariat Energie Atomique Procede et systeme de lecture d'un ensemble dynamique d'etiquettes portant des codes d'identification distincts
FR2805637B1 (fr) * 2000-02-25 2002-12-13 Commissariat Energie Atomique Procede de lecture d'etiquettes electroniques par identification simultanee de leur code
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1567994B1 (en) * 2002-11-15 2012-05-09 Sensitech Inc. Rf identification tag for communicating condition information associated with an item
FR2859843B1 (fr) * 2003-09-16 2005-12-23 Commissariat Energie Atomique Dispositif adressable par radiofrequence, systeme comportant une pluralite de tels dispositifs agences dans l'espace et procede d'adressage par activation d'un mode transparent

Similar Documents

Publication Publication Date Title
JP2007533299A5 (https=)
Vattepu et al. Sialylation as an important regulator of antibody function
AU2004283924B2 (en) Correlation between the fucose content / galactose content ratio of anti-rhesus-D and anti-HLA-DR antibodies and the ADCC activity
Jefferis Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Pincetic et al. Type I and type II Fc receptors regulate innate and adaptive immunity
Anthony et al. Novel roles for the IgG Fc glycan
Arnold et al. The impact of glycosylation on the biological function and structure of human immunoglobulins
Jefferis Glycosylation as a strategy to improve antibody-based therapeutics
Buettner et al. Improving immunotherapy through glycodesign
JP6461808B2 (ja) 炎症および細菌感染症処置におけるモノクローナル抗体の使用
PT1176195E (pt) Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
JP6480926B2 (ja) タンパク質におけるフコシル化レベルを制御するための方法
JP2011506476A (ja) 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法
TW201202266A (en) Method for preparing antibodies having improved properties
JP2009512694A5 (https=)
TW201506041A (zh) 高度半乳糖基化的抗腫瘤壞死因子阿爾法抗體及其用途
Manabe et al. Systematic preparation of a 66-IgG library with symmetric and asymmetric homogeneous glycans and their functional evaluation
US20100323368A1 (en) Cytokine production-inducing antibody
JP2010512306A (ja) 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
Nimmerjahn et al. Sweet rules: linking glycosylation to antibody function
US20250313646A1 (en) Glycoengineered antibodies
Nimmerjahn Role of Antibody Glycosylation in Health, Disease, and Therapy
Jefferis Characterization of biosimilar biologics: the link between structure and functions
Suzuki Glycan Structures of Human Immunoglobulins and Their Roles
Lydyard The effect on IgG glycosylation of altering 1, 4-galactosyltransferase-1 activity in B cells